One RWE-al headache: combating chronic migraines via combination treatment

Written by Lana Shkak, Commissioning Editor


The findings of a real-world study, published in Frontiers in Neurology, revealed that onabotulinumtoxinA was effective at reducing monthly headache days (MHD) and that this, in combination with a calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb), was safe and reduced MHD further. Chronic migraine (CM) affects approximately 1–2% of the population globally and patients are limited in their ability to perform daily activities. In the past, research has shown that lifestyles modifications, comorbidity management and appropriate treatment can help manage the condition. The researchers explained that onabotulinumtoxinA was first approved as a treatment for migraine prevention in 2010, and “in...

To view this content, please register now for access

It's completely free